Coya Therapeutics shares rise 1.61% intraday after FDA IND clearance for ALS trial and strategic partnerships.

Coya Therapeutics, Inc. rose 1.61% in intraday trading, with the company's CEO, Arun Swaminathan, discussing recent progress and strategic vision in an exclusive Q&A with PRISM MarketView. The interview highlighted FDA acceptance of the Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS), enabling the initiation of a Phase 2 clinical trial, and strategic partnerships, including with Dr. Reddy’s Laboratories, which provide financial support.